Premium
Increased plasma monocyte chemoattractant protein‐1 level in idiopathic pulmonary arterial hypertension
Author(s) -
ITOH Takefumi,
NAGAYA Noritoshi,
ISHIBASHIUEDA Hatsue,
KYOTANI Shingo,
OYA Hideo,
SAKAMAKI Fumio,
KIMURA Hiroshi,
NAKANISHI Norifumi
Publication year - 2006
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1111/j.1440-1843.2006.00821.x
Subject(s) - medicine , monocyte , chemokine , tumor necrosis factor alpha , pulmonary hypertension , cardiology , hemodynamics , inflammation , gastroenterology , endocrinology
Objective: Monocyte chemoattractant protein‐1 (MCP‐1), a pro‐inflammatory chemokine, has potent chemoattractant activity for monocytes/macrophages. We sought to investigate the clinical significance of MCP‐1 in idiopathic pulmonary arterial hypertension (IPAH). Methods: This study included 28 patients with IPAH, seven patients with pulmonary arterial hypertension (PAH) related to collagen vascular disease, and 13 healthy subjects. Plasma MCP‐1 levels were measured together with serum IL‐6 and tumour necrosis factor‐α (ΤΝF‐α) levels. Results: Circulating levels of MCP‐1, IL‐6 and ΤΝF‐α were significantly higher in patients with IPAH than in healthy controls, although they were lower than in patients with PAH related to collagen vascular disease. Plasma MCP‐1 did not significantly correlate with any haemodynamic variables. However, plasma MCP‐1 levels correlated negatively with the disease duration (time from symptom onset). Conclusions: Plasma MCP‐1 levels were elevated in patients with IPAH, and this elevation was particularly marked in the early stage of disease. Taking into account the chemoattractant activity of MCP‐1, these results imply a contribution of MCP‐1 to the development of pulmonary hypertension.